Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.
Joined February 2009
- Tweets 23,190
- Following 740
- Followers 29,987
- Likes 3,736
4,922 Photos and videos
Pinned Tweet
May 27
🩸 What will be the hematologic oncology data to look out for at #ASCO26?
Join @docbraunstein and @SofiaZahid26 for a live X Spaces discussion on the key presentations in multiple myeloma, leukemia, CAR T-cell therapy, and DLBCL at this year's meeting!
Tune in 5/30 at 5:30 PM EST / 4:30 PM CST.
@nyulangone
x.com/i/spaces/1DGleeXwrQrJL
1
1
2,559
🧐Could CD20×CD3 bispecific antibodies potentially replace conventional bridging strategies prior to CAR T-cell therapy in large B-cell lymphoma?
Data presented at #EHA2026 suggest that the use of bispecifics correlated with lower hematologic toxicity, higher responses, and preserved CAR T fitness in LBCL groups.
Read the full results below:
cancernetwork.com/view/cd20-…
#lymsm
2
2
188
🤔 Is it feasible to replace 2 intensive conventional chemotherapy courses with blinatumomab among pediatric patients with high-risk B-ALL?
Data presented at #EHA2026 demonstrated safety and improved EFS outcomes when making the switch!
Read the full results below:
cancernetwork.com/view/blina…
#leusm
116
The FDA has granted priority review to atezolizumab/atezolizumab and hyaluronidase plus chemo as adjuvant treatment of stage III dMMR/MSI-H colon cancer.
hubs.ly/Q04ldS7R0
#crcsm #oncology #cancer
1
175
🩸 Talquetamab plus daratumumab, with or without pomalidomide, improved PFS among patients with relapsed/refractory multiple myeloma.
Data from the MonumenTAL-3 trial highlighted at #EHA2026 support these regimens as new standards of care for patients as early as first relapse.
Dive into the full results below:
cancernetwork.com/view/talqu…
#mmsm
1
132
VT-EBV-N yields durable DFS vs plasma blood mononuclear cell therapy in EBV extranodal NK/T-cell lymphoma that experienced CR within 6 months of enrollment.
hubs.li/Q04ldxhf0
#lymsm #lymphoma #EHA2026
1
1
92
Jun 12
The DKRd regimen demonstrated efficacy among patients with high-risk smoldering multiple myeloma.
Data from the ASCENT trial presented at #EHA2026 showed the potential benefits of a limited-duration combination in this treatment setting.
Check out the full results below:
cancernetwork.com/view/quadr…
#mmsm | @myelomaMD
147
Jun 12
The @US_FDA has approved capivasterib plus abiraterone and prednisone for patients with PTEN- deficient metastatic hormone-sensitive prostate cancer. #pcsm | @FDAOncology
cancernetwork.com/view/capiv…
1
83
Jun 12
🚨 The FDA has approved adjuvant belzutifan plus pembrolizumab for patients with ccRCC who have an intermediate or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.
hubs.li/Q04ldVTj0
#kcsm #oncology #cancer | @ASCO
88
Jun 12
Chemotherapy Regimen Shows Early Efficacy in Adenoid Cystic Carcinoma 🔍
Investigators in a recent single-arm phase 2 study evaluated a combination regimen utilizing liposomal doxorubicin plus nab-paclitaxel, both with and without subsequent chemoradiotherapy, treating head and neck adenoid cystic carcinoma (ACC).
The study met its primary end point of ORR and conferred the following outcomes:
➡️ 90.3% ORR, 48.4% CR rate
➡️ 25.7 month median PFS
➡️ No Grade 4 or higher TRAEs
#Oncology #HeadAndNeckCancer #CancerResearch #ClinicalTrial #MedEd
97
Jun 12
In the phase 3 HEALER/KN026-003 trial, anbenitamab plus HB1801:
⭐ Significantly prolonged PFS vs THP
⭐ Showed favorable trend for OS vs THP
📆 Full results will be shared at an upcoming conference
hubs.ly/Q04l6_h-0
#bcsm #BreastCancer #oncology
1
108
Jun 11
The external data monitoring committee recommended termination of the KEYNOTE-D46/EVOKE-03 study after sacituzumab govitecan plus pembrolizumab did not reach statistical significance for PFS in previously untreated metastatic PD-L1 NSCLC.
⬇️ Read more ⬇️
hubs.li/Q04kYFDX0
#lcsm #NSCLC #oncology
1
180
Jun 11
Tisa-cel yielded enduring remissions among pediatric and young patients with high-risk B-ALL.
Findings from the phase 2 CASSIOPEIA trial showed potential OS and DFS benefits with tisa-cel after frontline consolidation therapy.
Check out the full results below:
cancernetwork.com/view/tisa-…
#EHA2026 #leusm | @EHA_Hematology
88
Jun 11
🚨 ICYMI: This week's podcast featured highlights from our #ASCO26 X Space on #mmsm #leusm and #lymsm.
Tune in for a discussion with:
⭐ Marc J. Braunstein, MD, PhD (@docbraunstein)
⭐ Sofia Zahid, MD (@SofiaZahid26)
hubs.li/Q04k-YKp0
🎙️ Available now Spotify and Apple Podcasts!
2
1
137
Jun 11
Infographic for review:
At the #ASCO26 Annual Meeting, investigators presented findings from a subgroup analysis of the phase 3 CABINET trial, which showcased efficacy with cabozantinib across neuroendocrine tumors (NETs) regardless of functional status.
Key findings included:
👉9.4-month vs 3.1-month PFS for non-functional NETs
👉12.7-month vs 5.4-month PFS for functional NETs
👉Consistent safety profile across all NETs populations
#NETs #cabozantinib #CABINETtrial
114
Jun 10
TIL therapy is changing melanoma treatment. 🧬22% of patients alive beyond 4 years with lifileucel (FDA-approved 2024) - even after failing chemo. Read more here hubs.li/Q04kTDlg0
#Melanoma #Oncology #Immunotherapy
1
1
1
178
Jun 10
China's NMPA has granted IND clearance to ADRX-0405, a next-generation ADC, for late-stage solid tumors, including metastatic castration-resistant prostate cancer.
This clearance enables Chinese centers to join the ongoing phase 1a/1b trial (NCT06710379) evaluating the agent.
hubs.li/Q04kPjHv0
#pcsm #oncology #cancer
135